KPV
Lysine-Proline-Valine (α-MSH C-terminal Tripeptide)
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
A short tripeptide derived from alpha-MSH, studied in animal and laboratory research for anti-inflammatory mechanisms — particularly in the gut — including NF-κB pathway-related work. These preclinical findings do not establish human intestinal benefit.
Plain English
Researchers study KPV because it is a small fragment of the natural anti-inflammatory peptide alpha-MSH. In animal models and laboratory experiments, researchers have investigated whether it can influence inflammatory signaling, including NF-κB-related pathways, and intestinal-barrier processes. The current evidence set does not establish human therapeutic benefit or a generalized human safety profile.
Overview
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Published evidence in this record is limited to animal and in-vitro/mechanistic research, including murine inflammatory bowel disease models, human bronchial epithelial cells in vitro, and PepT1-mediated intestinal uptake studies. These sources do not establish human therapeutic efficacy, oral clinical bioavailability, or exceptional safety.
Research Summary
KPV has preclinical and mechanistic evidence in this record. Murine inflammatory bowel disease work, in-vitro bronchial epithelial research, and intestinal uptake experiments support further investigation of anti-inflammatory mechanisms, but do not establish human therapeutic efficacy, oral clinical bioavailability, or chronic safety.
Research Areas
- Preclinical inflammatory-signaling and intestinal-uptake research
Safety & Risks
Serious Risks
- Current evidence in this record is animal and in-vitro; human safety has not been established.
Legal Status by Region
- United States
- Not FDA approved. The HHS interim 503A policy describes conditional enforcement discretion specifically for KPV acetate in topical and oral dosage forms, not injectable use or other forms by inference. This is not proof of safety, effectiveness or human oral bioavailability, or blanket compounding legality. The Federal Register notice describes a draft, nonbinding policy; no effective date is asserted here. Conditions include a patient-specific prescription; a State-licensed pharmacy, Federal facility or licensed physician; the exact Appendix B identity and route; FDA-registered original API manufacture compliant with CGMP, valid COAs, required quality testing and supplier validation; reporting compounded products, serious adverse events and quality issues to FDA and relevant States; patient reporting instructions and labeling 'This is a compounded drug product. Not for resale.'; a single Appendix A active ingredient; formulation-specific documentation of adequate human oral bioavailability for oral products; only a 510(k)-cleared syringe if a delivery device is co-packaged or contains the drug; and all other applicable FD&C Act requirements. This is not a 503B authorization. The interim policy lasts until a final rule addresses the substance and may be revisited for safety or quality signals.
- United Kingdom
- Current authorization status not established in this record
- Australia
- Current authorization status not established in this record
- Canada
- Current authorization status not established in this record
Citations & Sources
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
2008
PMID 18092346
- Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.
2012
PMID 22837805
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D · Gastroenterology · 2008
PMID 18061177 · DOI 10.1053/j.gastro.2007.10.026
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendices A and B
U.S. Department of Health and Human Services · HHS
- Public inspection notice: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (filed October 28, 2026; scheduled publication October 30, 2026; not an effective-date determination)
U.S. Department of Health and Human Services · Federal Register — Public Inspection
Regulatory FR Doc. 2026-22192